Phase I study of nivolumab (nivo) plus nab-paclitaxel (nab-P) in solid tumors: results from the pancreatic cancer (PC) and non-small cell lung cancer (NSCLC) cohorts

被引：1
|
作者：
George, B. [1 ,2 ]
Kelly, K. [3 ]
Ko, A. [4 ]
Soliman, H. [5 ]
Trunova, N. [6 ]
Wainberg, Z. [7 ]
Waterhouse, D. [8 ]
O'Dwyer, P. [9 ]
Hochster, H. [10 ]
机构：
[1] Froedtert, Div Hematol & Oncol, Milwaukee, WI USA
[2] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[3] Univ Calif Davis, Ctr Comprehens Canc, Internal Med, Sacramento, CA USA
[4] Celgene Corp, Biostats, Summit, NJ USA
[5] Univ S Florida, Moffitt Canc Ctr, Tampa, FL USA
[6] Celgene Corp, Med Affairs, Summit, NJ USA
[7] Univ Calif Los Angeles, David Geffen Sch Med, Internal Med, Los Angeles, CA 90095 USA
[8] Oncol Hematol Care, Med Oncol, Cincinnati, OH USA
[9] Univ Penn, Abramson Canc Ctr, Med, Philadelphia, PA 19104 USA
[10] Yale Canc Ctr, Med Oncol, New Haven, CT USA
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw378.13
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1059P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC)
    Morgensztern, D.
    Ong, T. J.
    Dols, M. Cobo
    Aix, S. Ponce
    Postmus, P. E.
    Lewanski, C.
    Bennouna, J.
    Fischer, J. R.
    Vidal, O. J.
    Stewart, D. J.
    Fasola, G.
    Ardizoni, A.
    Weaver, J.
    Wolfsteiner, M.
    Talbot, D.
    Govindan, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [32] Results of a randomized, phase III trial of nab-paclitaxel (nab-P) and carboplatin (C) compared with cremophor-based paclitaxel (P) and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC)
    Socinski, M. A.
    Bondarenko, I. N.
    Karaseva, N. A.
    Makhson, A.
    Vynnichenko, I.
    Okamoto, I.
    Hon, J. K.
    Hirsh, V.
    Bhar, P.
    Iglesias, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [33] A phase I study of two different schedules of nab-paclitaxel (nab-P) with ascending doses of vandetanib (V) with expansion in patients (Pts) with pancreatic cancer (PC).
    El-Khoueiry, A. B.
    Iqbal, S.
    Lenz, H.
    Gitlitz, B. J.
    Yang, D.
    Cole, S.
    Duddalwar, V.
    Garcia, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [34] A pilot phase II multicenter study of nab-paclitaxel (Nab-P) and gemcitabine (G) as preoperative therapy for potentially resectable pancreatic cancer (PC)
    MacKenzie, Shawn
    Zeh, Herbert
    McCahill, Laurence E.
    Sielaff, Timothy D.
    Bahary, Nathan
    Gribbin, Thomas Edward
    Seng, John E.
    Leach, Joseph W.
    Harmon, Jocelyn
    Demeure, Michael J.
    Von Hoff, Daniel D.
    Moser, A. Jim
    Ramanathan, Ramesh K.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [35] Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer
    Ho, Cheryl
    Davies, Angela M.
    Sangha, Randeep S.
    Lau, Derick
    Lara, Primo, Jr.
    Chew, Helen K.
    Beckett, Laurel
    Mack, Philip C.
    Riess, Jonathan W.
    Gandara, David R.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (06) : 1587 - 1591
  • [36] Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer
    Cheryl Ho
    Angela M. Davies
    Randeep S. Sangha
    Derick Lau
    Primo Lara
    Helen K. Chew
    Laurel Beckett
    Philip C. Mack
    Jonathan W. Riess
    David R. Gandara
    Investigational New Drugs, 2013, 31 : 1587 - 1591
  • [37] A phase II study of Chinese patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) for metastatic pancreatic cancer (MPC)
    Shen, Lin
    Yu, Xianjun
    Hao, Jihui
    Wang, Liwei
    Pan, Hongming
    Han, Guohong
    Xu, Jian-Ming
    Zhang, Yanqiao
    Yang, Shujun
    Chen, Jia
    Ying, Jieer
    Dai, Guanghai
    Li, Mingyu
    Begic, Damir
    Lu, Brian D.
    Xu, Ruihua
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [38] Nab-Paclitaxel Maintenance in Squamous Non-Small Cell Lung Cancer (NSCLC): Updated Results of the Phase III ABOUND.sqm Study
    Spigel, D.
    Jotte, R.
    Aix, S.
    Gressot, L.
    Morgensztern, D.
    Mccleod, M.
    Socinski, M.
    Daniel, D.
    Juan, O.
    Mileham, K.
    West, H.
    Page, R.
    Reinmuth, N.
    Knoble, J.
    Tian, O.
    Bhore, R.
    Wolfsteiner, M.
    Ong, T. Jin
    Gridelli, C.
    Thomas, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S301 - S301
  • [39] Carboplatin plus nab-paclitaxel for recurrent small cell lung cancer: A phase II study
    Ikeda, Naoya
    Arai, Ryo
    Soda, Sayo
    Inoue, Takashi
    Uchida, Nobuhiko
    Nakamura, Yusuke
    Masawa, Meitetsu
    Kushima, Yoshitomo
    Okutomi, Hiroaki
    Takemasa, Akihiro
    Shimizu, Yasuo
    Niho, Seiji
    THORACIC CANCER, 2022, 13 (09) : 1342 - 1348
  • [40] Safety and efficacy of nab-paclitaxel (nab-P)-based therapy in patients (pts) with non-small cell lung cancer (NSCLC) and performance status (PS) 2: Results from ABOUND.PS2.
    Gajra, Ajeet
    Karim, Nagla Abdel
    Mulford, Deborah A.
    Villaruz, Liza Cosca
    Matrana, Marc Ryan
    Ali, Haythem Y.
    Santos, Edgardo S.
    Ong, Teng Jin
    Sanford, Alexandra
    Amiri, Katayoun
    Spigel, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345